乳腺癌診治現狀與展望_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

李凡 ,  任國勝

重慶醫科大學附屬第一醫院內分泌乳腺外科（重慶 400016）;

Corresponding?author：

任國勝, Email: rengs726@163.com

Keywords：

DOI：

10.7507/1007-9424.201909068

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 李凡, 任國勝. 乳腺癌診治現狀與展望. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2019, 26(12): 1393-1397. doi: 10.7507/1007-9424.201909068 Copy

1.	孫可欣, 鄭榮壽, 張思維, 等. 2015 年中國分地區惡性腫瘤發病和死亡分析. 中國腫瘤, 2019, 28(1): 1-11.
2.	中國抗癌協會乳腺癌專業委員會. 中國抗癌協會乳腺癌診治指南與規范(2017 年版). 中國癌癥雜志, 2017, 27(9): 695-759.
3.	中國臨床腫瘤學會指南工作委員會. 中國臨床腫瘤學會(CSCO)乳腺癌診療指南(2018.V1). 北京: 人民衛生出版社, 2018: 21-93.
4.	Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med, 2003, 349(6): 546-553.
5.	Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase3 trial. Lancet Oncol, 2010, 11(10): 927-933.
6.	Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med, 1993, 328(22): 1587-1591.
7.	Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage Ⅰ-Ⅱ breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol, 2012, 13(4): 412-419.
8.	Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages Ⅰ and Ⅱ invasive breast cancer. Int J Radiat Oncol Biol Phys, 2014, 88(3): 553-564.
9.	中國抗癌協會乳腺癌專業委員會. 乳腺腫瘤整形與乳房重建專家共識(2018 年版). 中國癌癥雜志, 2018, 28(6): 439-480.
10.	Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 2010, 375(9712): 377-384.
11.	Vriens BEPJ, Vriens IJH, Aarts MJB, et al. Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer. Breast Cancer Res Treat, 2017, 165(3): 593-600.
12.	Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol, 2016, 17(6): 791-800.
13.	Pertuzumab SZ. Trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: efficacy and safety analysis of a randomized phase Ⅲ study in Asian patients (PEONY). San Antonio, 2018.
14.	Mamounas EP. NSABP breast cancer clinical trials: recent results and future directions. Clin Med Res, 2003, 1(4): 309-326.
15.	Yang HJ, Yu XF, He XM, et al. Age interactions in breast cancer: an analysis of a 10-year multicentre study in China. J Int Med Res, 2012, 40(3): 1130-1140.
16.	NCCN. NCCN Clinical Practice Guidelines in Oncology Breast Cancer 2019. V3. 2019-09-09. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
17.	Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline focused update. J Clin Oncol, 2019, 37(5): 423-438.
18.	Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline update on ovarian suppression. J Clin Oncol, 2016, 34(14): 1689-1701.
19.	Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol, 2014, 32(33): 3744-3752.
20.	Skedgel C, Rayson D, Younis T. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial. Value Health, 2009, 12(5): 641-648.
21.	Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol, 2013, 14(6): 461-471.
22.	Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol, 2012, 13(1): 25-32.
23.	Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 2012, 379(9816): 633-640.
24.	Shao Z, Pang D, Yang H, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: efficacy and safety analysis of a randomized phase Ⅲ study in Asian patients (PEONY). Cancer Res, 2019, 79(4 Suppl): 6-17.
25.	Pistilli B, Mazouni C, Zingarello A, et al. Individualized prediction of menses recovery after chemotherapy for early-stage breast cancer: a nomogram developed from UNICANCER PACS04 and PACS05 trials. Clin Breast Cancer, 2019, 19(1): 63-70.
26.	Sperinde J, Huang W, Vehtari A, et al. p95HER2 methionine 611 carboxy-terminal fragment is predictive of trastuzumab adjuvant treatment benefit in the FinHer trial. Clin Cancer Res, 2018, 24(13): 3046-3052.
27.	Sonnenblick A, Bailey A, Uziely B, et al. Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA trial. Anticancer Res, 2019, 39(2): 797-802.
28.	Hurvitz SA, Betting DJ, Stern HM, et al. Analysis of Fcγ receptor Ⅲa and Ⅱa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res, 2012, 18(12): 3478-3486.
29.	Yankulina O, Zullo AR, Cabral SE, et al. Pertuzumab-associated diarrhea in HER2/neu-positive breast cancer patients: a comparison of trials to actual practice. J Oncol Pharm Pract, 2019, [Epub ahead of print].
30.	Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase Ⅱ TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer, 2018, 89: 27-35.
31.	Swain SM, Tang G, Lucas PC, et al. Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination. Breast Cancer Res Treat, 2019, 178(2): 389-399.
32.	Ignatiadis M, Van den Eynden G, Roberto S, et al. Tumor-infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: a TRYPHAENA substudy. J Natl Cancer Inst, 2019, 111(1): 69-77.
33.	Kim S, Kim J, Park HS, et al. An updated nomogram for predicting invasiveness in preoperative ductal carcinoma in situ of the breast. Yonsei Med J, 2019, 60(11): 1028-1035.
34.	Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol, 2011, 29(16): 2144-2149.
35.	Gennari A, D’amico M, Corradengo D. Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review. Ther Adv Med Oncol, 2011, 3(5): 229-232.
36.	Marty M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 2005, 23(19): 4265-4274.
37.	Arslan C, Sari E, Aksoy S, et al. Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets, 2011, 15(1): 21-30.
38.	Wang J, Zheng R, Wang Z, et al. Efficacy and safety of vinorelbine plus cisplatin vs. gemcitabine plus cisplatin for treatment of metastatic triple-negative breast cancer after failure with anthracyclines and taxanes. Med Sci Monit, 2017, 23: 4657-4664.

1. 孫可欣, 鄭榮壽, 張思維, 等. 2015 年中國分地區惡性腫瘤發病和死亡分析. 中國腫瘤, 2019, 28(1): 1-11.
2. 中國抗癌協會乳腺癌專業委員會. 中國抗癌協會乳腺癌診治指南與規范(2017 年版). 中國癌癥雜志, 2017, 27(9): 695-759.
3. 中國臨床腫瘤學會指南工作委員會. 中國臨床腫瘤學會(CSCO)乳腺癌診療指南(2018.V1). 北京: 人民衛生出版社, 2018: 21-93.
4. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med, 2003, 349(6): 546-553.
5. Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase3 trial. Lancet Oncol, 2010, 11(10): 927-933.
6. Veronesi U, Luini A, Del Vecchio M, et al. Radiotherapy after breast-preserving surgery in women with localized cancer of the breast. N Engl J Med, 1993, 328(22): 1587-1591.
7. Litière S, Werutsky G, Fentiman IS, et al. Breast conserving therapy versus mastectomy for stage Ⅰ-Ⅱ breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol, 2012, 13(4): 412-419.
8. Moran MS, Schnitt SJ, Giuliano AE, et al. Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages Ⅰ and Ⅱ invasive breast cancer. Int J Radiat Oncol Biol Phys, 2014, 88(3): 553-564.
9. 中國抗癌協會乳腺癌專業委員會. 乳腺腫瘤整形與乳房重建專家共識(2018 年版). 中國癌癥雜志, 2018, 28(6): 439-480.
10. Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet, 2010, 375(9712): 377-384.
11. Vriens BEPJ, Vriens IJH, Aarts MJB, et al. Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer. Breast Cancer Res Treat, 2017, 165(3): 593-600.
12. Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol, 2016, 17(6): 791-800.
13. Pertuzumab SZ. Trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: efficacy and safety analysis of a randomized phase Ⅲ study in Asian patients (PEONY). San Antonio, 2018.
14. Mamounas EP. NSABP breast cancer clinical trials: recent results and future directions. Clin Med Res, 2003, 1(4): 309-326.
15. Yang HJ, Yu XF, He XM, et al. Age interactions in breast cancer: an analysis of a 10-year multicentre study in China. J Int Med Res, 2012, 40(3): 1130-1140.
16. NCCN. NCCN Clinical Practice Guidelines in Oncology Breast Cancer 2019. V3. 2019-09-09. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
17. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO Clinical Practice Guideline focused update. J Clin Oncol, 2019, 37(5): 423-438.
18. Burstein HJ, Lacchetti C, Anderson H, et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline update on ovarian suppression. J Clin Oncol, 2016, 34(14): 1689-1701.
19. Perez EA, Romond EH, Suman VJ, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol, 2014, 32(33): 3744-3752.
20. Skedgel C, Rayson D, Younis T. The cost-utility of sequential adjuvant trastuzumab in women with Her2/Neu-positive breast cancer: an analysis based on updated results from the HERA Trial. Value Health, 2009, 12(5): 641-648.
21. Swain SM, Kim SB, Cortés J, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol, 2013, 14(6): 461-471.
22. Gianni L, Pienkowski T, Im YH, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol, 2012, 13(1): 25-32.
23. Baselga J, Bradbury I, Eidtmann H, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet, 2012, 379(9816): 633-640.
24. Shao Z, Pang D, Yang H, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive early or locally advanced breast cancer in the neoadjuvant setting: efficacy and safety analysis of a randomized phase Ⅲ study in Asian patients (PEONY). Cancer Res, 2019, 79(4 Suppl): 6-17.
25. Pistilli B, Mazouni C, Zingarello A, et al. Individualized prediction of menses recovery after chemotherapy for early-stage breast cancer: a nomogram developed from UNICANCER PACS04 and PACS05 trials. Clin Breast Cancer, 2019, 19(1): 63-70.
26. Sperinde J, Huang W, Vehtari A, et al. p95HER2 methionine 611 carboxy-terminal fragment is predictive of trastuzumab adjuvant treatment benefit in the FinHer trial. Clin Cancer Res, 2018, 24(13): 3046-3052.
27. Sonnenblick A, Bailey A, Uziely B, et al. Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA trial. Anticancer Res, 2019, 39(2): 797-802.
28. Hurvitz SA, Betting DJ, Stern HM, et al. Analysis of Fcγ receptor Ⅲa and Ⅱa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res, 2012, 18(12): 3478-3486.
29. Yankulina O, Zullo AR, Cabral SE, et al. Pertuzumab-associated diarrhea in HER2/neu-positive breast cancer patients: a comparison of trials to actual practice. J Oncol Pharm Pract, 2019, [Epub ahead of print].
30. Schneeweiss A, Chia S, Hickish T, et al. Long-term efficacy analysis of the randomised, phase Ⅱ TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer, 2018, 89: 27-35.
31. Swain SM, Tang G, Lucas PC, et al. Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination. Breast Cancer Res Treat, 2019, 178(2): 389-399.
32. Ignatiadis M, Van den Eynden G, Roberto S, et al. Tumor-infiltrating lymphocytes in patients receiving trastuzumab/pertuzumab-based chemotherapy: a TRYPHAENA substudy. J Natl Cancer Inst, 2019, 111(1): 69-77.
33. Kim S, Kim J, Park HS, et al. An updated nomogram for predicting invasiveness in preoperative ductal carcinoma in situ of the breast. Yonsei Med J, 2019, 60(11): 1028-1035.
34. Gennari A, Stockler M, Puntoni M, et al. Duration of chemotherapy for metastatic breast cancer: a systematic review and meta-analysis of randomized clinical trials. J Clin Oncol, 2011, 29(16): 2144-2149.
35. Gennari A, D’amico M, Corradengo D. Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review. Ther Adv Med Oncol, 2011, 3(5): 229-232.
36. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 2005, 23(19): 4265-4274.
37. Arslan C, Sari E, Aksoy S, et al. Variation in hormone receptor and HER-2 status between primary and metastatic breast cancer: review of the literature. Expert Opin Ther Targets, 2011, 15(1): 21-30.
38. Wang J, Zheng R, Wang Z, et al. Efficacy and safety of vinorelbine plus cisplatin vs. gemcitabine plus cisplatin for treatment of metastatic triple-negative breast cancer after failure with anthracyclines and taxanes. Med Sci Monit, 2017, 23: 4657-4664.

Previous Article
再次雙瓣膜置換聯合主動脈幕簾重建術一例
Next Article
乳腺癌的區域外科治療

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

乳腺癌診治現狀與展望

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content